Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1 2Phase 4 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 33Neoplasms 17Prostatic Neoplasms 14Lung Neoplasms 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 10Multiple Myeloma 9Colorectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Papillomavirus Infections 6Pain, Postoperative 6Neoplasm Metastasis 6Leukemia, Myeloid, Acute 6Stomach Neoplasms 5Recurrence 5Liver Neoplasms 5Lymphoma, Non-Hodgkin 4Kidney Neoplasms 4Heart Failure 4Glioma 4Febrile Neutropenia 4Carcinoma, Renal Cell 4Brain Neoplasms 4Warts 3Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Skin Neoplasms 3Rectal Neoplasms 3Pituitary Neoplasms 3Pancreatic Neoplasms 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Carcinoma, Medullary × Clear all
NCT05830500 2023-07-25

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 4 Recruiting
360 enrolled

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡